Table 5.
mAbs used | Cancer types |
---|---|
MEM-E/02 | Melanoma(86) |
Lip squamousal cell carcinoma(87) | |
Laryngeal carcinoma(88) | |
Vulvar intraepithelial carcinoma(76) | |
Penile cancer(89) | |
Glioblastomas(77,90,91) | |
Oral osteosarcoma(92) | |
Intraoral mucoepidermoid carcinoma(93) | |
Rectal cancer(94) | |
Colorectal carcinoma(78,95–99) | |
Colon carcinoma(97) | |
Hepatocellular carcinoma(100) | |
Nonsmall cell lung carcinoma(101) | |
Breast cancer(102,103) | |
Ovarian cancer/cervical cancer(104) | |
Cervical cancer(105,106) | |
Cervical squamosal and adenocarcinoma(107) | |
Serous ovarian adenocarcinoma(108,109) | |
Renal cell carcinoma(110,111) | |
Thyroid cancer(112) | |
Hodgkin lymphoma(113) | |
3D12 | Many cancers(114) |
Melanoma, cervical cancers(115) | |
Glioblastoma stem cells(116) | |
Glioblastoma(117) | |
Neuroblastoma(118) | |
Chronic lymphocytic leukemia(119,120) | |
3H2679 | Neuroblastoma(121) |
Colorectal carcinoma(122) | |
MEM-E/06 | Colon carcinoma and leukemia (K562)(123) |
MEM-E/07 and MEM-E/08 | Melanoma and other cancers(123) |
MEM-E/08 | Colorectal carcinoma(124,125) |
TFL-033 and MEM-E/02 | Gastric cancer(126) melanoma(54) |
mAbs, monoclonal antibodies.